HR 948: House Study Committee on Pharmacy Benefits Managers and Consumer Access to Prescription Medications; create
Last action March 9, 2026 · House Passed/Adopted By Substitute
A Georgia House resolution creates a study committee to examine pharmacy benefits managers and their effect on Georgians' access to prescription drugs, with a report due by December 2026.
The summaries below were written by an AI model (claude-sonnet-5) from the text of the resolution and are not part of it. Quote the text, not the summary. The stored text is the Comm Sub version, the latest LegiScan holds.
In plain language
This resolution sets up the House Study Committee on Pharmacy Benefits Managers and Consumer Access to Prescription Medications. Pharmacy benefits managers, or PBMs, are companies that administer prescription drug insurance benefits, negotiate with drug makers and pharmacies, and decide which drugs are covered and which pharmacies patients can use. The resolution cites concerns that PBMs steer patients toward pharmacies they own, mark up drug prices far above national averages for some medications, and may be contributing to counties in Georgia having no local pharmacy at all. The committee will include House leaders and appointed members or experts, and it is directed to study these issues and recommend legislation if it chooses. Members get standard state travel and meeting allowances, and the committee must file any report before it is abolished on December 1, 2026.
What the bill does
- Creates the House Study Committee on Pharmacy Benefits Managers and Consumer Access to Prescription Medications to examine PBM practices in Georgia.
- Sets committee membership as the chairs of the House Appropriations and Health Committees plus three more members or experts appointed by the Speaker.
- Directs the committee to study PBM-related problems and recommend legislation or other action it deems necessary.
- Authorizes standard legislative allowances and expense reimbursement for members under existing Georgia code sections, capped at five days unless extended.
- Requires any approved findings or legislative recommendations to be filed as a report with the Clerk of the House before the committee ends.
- Abolishes the committee automatically on December 1, 2026.
Who it affects
Pharmacy benefits managers operating in Georgia, independent and affiliate pharmacies, patients who rely on prescription drug coverage, insurers and employers who contract with PBMs, and members of the Georgia House of Representatives who will serve on or oversee the new study committee.
Why it matters
The committee itself changes no law, but its findings could shape future legislation on drug pricing, pharmacy access, and PBM regulation in Georgia, an issue tied to rising drug costs and counties losing local pharmacies.
Key provisions
- Paragraph (1) formally creates the study committee.
- Paragraph (2) sets membership: two committee chairs plus three Speaker-appointed members or experts, with a Speaker-designated chairperson.
- Paragraph (3) charges the committee with studying PBM issues and recommending legislation.
- Paragraph (5) details allowances, capping standard reimbursement at five days unless extended, funded through House appropriations or members' own agencies.
- Paragraph (6) requires any adopted report or recommendations to be filed with the Clerk of the House before abolishment, or minutes filed if no report is approved.
- Paragraph (7) sets the committee's abolishment date as December 1, 2026.
From the bill
“pharmacy benefits managers continue to steer patients to pharmacy benefits manager affiliate pharmacies within this state”
“markups of thousands of percent above the national average drug acquisition costs for medications used to treat multiple sclerosis, cancer, and kidney disease”
Status timeline
- House Passed/Adopted By Substitute (House)
- House Third Readers (House)
- House Committee Favorably Reported By Substitute (House)
- House Second Readers (House)
- House First Readers (House)
- House Hopper (House)
Sponsors
- Ron Stephens (R, HD-164)
- Trey Kelley (R, HD-016)
- Lee Hawkins (R, HD-027)
- Debbie Buckner (D, HD-137)
- Mark Newton (R, HD-127)
Votes
- House voteMarch 9, 2026
157 yea, 0 nay (3 not voting, 17 absent)
Topics
- pharmacy benefits managers
- prescription drug prices
- pharmacy access
- health policy
- legislative study committees